Health · 1 sources covering this

STAT+: J&J spends $1 billion to enter KRAS race for cancer treatments

Johnson & Johnson said it will purchase the startup Firefly Bio for $1 billion in an effort to expand its work in the suddenly buzzy field of KRAS inhibitors.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·2h ago
STAT+: J&J spends $1 billion to enter KRAS race for cancer treatments
Johnson & Johnson said it will purchase the startup Firefly Bio for $1 billion in an effort to expand its work in the suddenly buzzy field of KRAS inhibitors.
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/c507453bf2fd53951bf5c9245ea29d0c669fd36c"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: J&#038;J spends $1 billion to enter KRAS race for cancer treatments"></iframe>

STAT+: J&J spends $1 billion to enter KRAS race for cancer treatments

How 1 sources are covering this

STAT+: J&J spends $1 billion to enter KRAS race for cancer treatments

More from Health

STAT+: UnitedHealthcare’s lactation billing feud, and fake strokes

STAT+: Novo underwhelmed by drug it once fought Pfizer for

STAT+: Pharmalittle: We’re reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and more

Major readouts from the annual diabetes conference

Reader

Trust & legal

Across the network

How 1 sources are covering this

STAT+: J&#038;J spends $1 billion to enter KRAS race for cancer treatments

More from Health

STAT+: UnitedHealthcare’s lactation billing feud, and fake strokes

STAT+: Novo underwhelmed by drug it once fought Pfizer for

STAT+: Pharmalittle: We&#8217;re reading about Lilly and Pfizer obesity drug data, Roche and J&#038;J deals, and more

Major readouts from the annual diabetes conference

Reader

Trust & legal

Across the network

STAT+: J&J spends $1 billion to enter KRAS race for cancer treatments

STAT+: Pharmalittle: We’re reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and more